T-cell receptor


Also found in: Dictionary, Thesaurus, Medical, Legal, Acronyms, Wikipedia.

T-cell receptor

[′tē ‚sel ri‚sep·tər]
(immunology)
Protein on the surface of T lymphocytes that specifically recognizes molecules of the major histocompatibility complex, either alone or in association with foreign antigens. Abbreviated TCR.
References in periodicals archive ?
4] Nonstandard abbreviations: SCID, severe combined immunodeficiency; TREC, T-cell receptor excision circle; NBS, newborn screening.
The companies entered a research collaboration and licensing agreement in January 2014 to develop novel cancer therapies using Immunocore's Immune Mobilizing Monoclonal T-Cell Receptor Against Cancer (ImmTAC) technology.
Detection of clonal rearrangement of T-cell receptor genes in the diagnosis of primary cutaneous CD30 lymphoproliferative disorders.
The structure of the killer T-cell receptor bound to the insulin peptide shows that the interaction is highly focused on just a small part of the molecule.
This case study is one of the first to investigate the use of polymerase chain reaction(PCR)for T-cell receptor (TCR) gene rearrangements in EATL/refractory CD and demonstrates that this approach will detect a clonal rearrangement in intestinal biopsies.
Reverse transcriptase-polymerase chain reaction can detect tumor markers in malignant cells in the form of specific chromosomal translocations (such as Philadelphia chromosome in chronic myeloid leukemia) and mutations (such as rearrangement of the T-cell receptor in non-Hodgkin's lymphoma).
Polymerase chain reaction testing showed that he did have a T-cell receptor gene rearrangement, but his lymphocytes were normal; so there was no evidence of cutaneous T-cell lymphoma.
Riether volunteered in a clinical study of the effects of a T-cell receptor vaccine on MS, and her symptoms improved.
They found that 15 of the sibling pairs had inherited the same two forms of the T-cell receptor gene from their parents and that only three pairs shared neither gene copy.
M2 EQUITYBITES-September 11, 2017-GSK exercises option to receive exclusive license for SPEAR T-cell receptor therapy from Adaptimmune
Immunocore will conduct a Phase lb/ II trial combining MedImmune's investigational checkpoint inhibitors MEDI4736 (anti-PD-L1) and/or tremelimumab (anti-CTLA-4) with IMCgp100, its lead T-cell receptor, for the potential treatment of patients with metastatic melanoma.

Full browser ?